Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials.

Diabetol Metab Syndr · 2015 · PMC4654794 · PMID 26594250

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Limitations There were trends for BMI to influence some efficacy measurements, which may be significant in studies with larger sample sizes (e.g. proportion of T2DM patients with HbA1c <7 % at trial endpoint at the unadjusted level).

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.